Phospholamban Ablation Using CRISPR-Cas9 System Improves Mortality in a Murine Heart Failure ModelReportar como inadecuado

Phospholamban Ablation Using CRISPR-Cas9 System Improves Mortality in a Murine Heart Failure Model - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Sarcoplasmic reticulum Ca2+-ATPase 2a SERCA2a and its inhibitory protein called phospholamban PLN are pivotal for Ca2+ handling in cardiomyocyte and are known that their expression level and activity were changed in the heart failure patients. To examine whether PLN inhibition can improve survival rate as well as cardiac function in heart failure, we performed PLN ablation in calsequestrin overexpressing CSQ-Tg mice, a severe heart failure model, using clustered regularly interspaced short palindromic repeat CRISPR-CRISPR-associated Cas system. According this method, generation rate of PLN wild type mice PLN copy >0.95 and PLN homozygous knockout KO mice PLN copy <0.05 were 39.1% and 10.5%, respectively. While CSQ overexpression causes severe heart failure symptoms and premature death, a significant ameliorating effect on survival rate was observed in PLN homozygous KO-CSQ-Tg mice compared to PLN wild type-CSQ-Tg mice median survival days are 55 and 50 days, respectively. Measurement of cardiac function with cardiac catheterization at the age of 5 weeks revealed that PLN ablation improved cardiac function in CSQ-Tg mice without affecting heart rate and blood pressure. Furthermore, increases in atrial and lung weight, an index of congestion, were significantly inhibited by PLN ablation. These results suggest that PLN deletion would be a promising approach to improve both mortality and cardiac function in the heart failure.

Autor: Manami Kaneko , Kentarou Hashikami, Satoshi Yamamoto, Hirokazu Matsumoto, Tomoyuki Nishimoto



Documentos relacionados